Incyte announces EU approval of Xencor-partnered lymphoma therapy
Source: SeekingAlpha
2025-12-17 11:52:55 ET
More on Incyte, Xencor
- Tracking Baker Brothers Portfolio - Q3 2025 Update
- Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow
- Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH - Slideshow
- FDA fast-tracks Incyte drug for rare blood cancer
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
Read the full article on Seeking Alpha
For further details see:
Incyte announces EU approval of Xencor-partnered lymphoma therapy
Xencor Inc.
NASDAQ: XNCR
XNCR Trading
1.04% G/L:
$11.62 Last:
256,311 Volume:
$11.72 Open:
XNCR Latest News
XNCR Stock Data
$902,628,328
68,011,331
N/A
68
N/A
Biotechnology & Life Sciences
Healthcare
US
Pasadena
